Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The purpose of this manuscript is to review the effects of sodium-glucose cotransport protein 2 inhibitors (SGLT2is) in patients with chronic kidney disease according to basic mechanisms, current recommendations, and future perspectives. Based on growing evidence from randomized, controlled trials, SGLT2is have proven their benefit on cardiac and renal adverse complications, and their indications expanded into the following five categories: glycemic control, reduction in atherosclerotic cardiovascular disease (ASCVD), heart failure, diabetic kidney disease, and nondiabetic kidney disease. Although kidney disease accelerates the progression of atherosclerosis, myocardial disease, and heart failure, so far, no specific drugs were available to protect renal function. Recently, two randomized trials, the DAPA-CKD and EMPA-Kidney, demonstrated the clinical benefit of the SGLT2is dapagliflozin and empagliflozin in improving the outcome in patients with chronic kidney disease. For the consistently positive results in cardiorenal protection, the SGLT2i represents an effective treatment to reduce the progression of kidney disease or death from cardiovascular causes in patients with and without diabetes mellitus.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218404 | PMC |
| http://dx.doi.org/10.3390/ijms24108732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A pediatric-onset case of chronic kidney disease caused by a novel sporadic variant and literature review.
Turk J Pediatr
September 2025
West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Background: The α-actinin-4 (ACTN4) gene encodes an actin-binding protein, which plays a crucial role in maintaining the structure and function of podocytes. Previous studies have confirmed that ACTN4 mutations can lead to focal segmental glomerulosclerosis-1 (FSGS1), a rare disease primarily manifesting in adolescence or adulthood, characterized by mild to moderate proteinuria, with some cases progressing slowly to end-stage renal disease.
Case Presentation: We report a 12.
Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.
Retina
September 2025
School of Mathematical and Computational Sciences, University of Prince Edward Island, Charlottetown, Canada.
Purpose: Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs.
View Article and Find Full Text PDFIdentifying Factors Associated with Subsequent Diagnosis of Adrenal Adenoma: a population-based historical case-control study.
Eur J Endocrinol
September 2025
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, 55905.
Objective: Identify social/metabolic risk factors associated with subsequent diagnosis of adrenal adenoma.
Design: Population-based historical case-control study.
Methods: Cases were adult patients diagnosed with an adrenal adenoma between 2005-2017 with no overt hormone excess.
A 12-Year Analysis of Equity and Efficiency in Living Kidney Donation at a Rural American Center.
Clin Transplant
September 2025
Avera Medical Group Transplant & Liver Surgery, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, USA.
Background: In the United States, a severe organ shortage precipitates an extensive transplant waitlist. Living donor kidneys are functionally superior to those from deceased donors and offer an alternative to close the supply-demand gap.
Methods: A retrospective review of 2147 patients who self-referred to begin the living kidney donation workup process at our center between June 1, 2012, and October 1, 2023 was conducted with subsequent statistical analysis of gathered data.
CaOx crystal nuclei are formed in rat outer cortex proximal tubules by a potential fibrinogen-dependent mechanism.
PLoS One
September 2025
Department of Urology, Kanazawa Medical University, Kahoku, Ishikawa, Japan.
Calcium oxalate (CaOx) stones are prevalent in urinary tract stone disease. While their formation can be induced in rats by administering ethylene glycol and vitamin D, the initial nucleation and formation processes are unclear. Here, we aimed to determine where CaOx crystals initially form, examine the associated histological and morphological changes, and clarify the genes whose expression varies at those sites and their function.
View Article and Find Full Text PDF